Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival

Jass, 2007, Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, 50, 113, 10.1111/j.1365-2559.2006.02549.x Leggett, 2010, Role of the serrated pathway in colorectal cancer pathogenesis, Gastroenterology, 138, 2088, 10.1053/j.gastro.2009.12.066 Samadder, 2013, Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women, Gastroenterology, 145, 348, 10.1053/j.gastro.2013.05.001 Samowitz, 2000, Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study, Cancer Epidemiol Biomarkers Prev, 9, 1193 Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 Ogino, 2009, KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803, Clin Cancer Res, 15, 7322, 10.1158/1078-0432.CCR-09-1570 Imamura, 2012, Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF-wild-type colorectal cancers, Clin Cancer Res, 18, 4753, 10.1158/1078-0432.CCR-11-3210 Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br J Cancer, 108, 1757, 10.1038/bjc.2013.118 Phipps, 2012, BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics, Cancer Epidemiol Biomarkers Prev, 21, 1792, 10.1158/1055-9965.EPI-12-0674 De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, 753, 10.1016/S1470-2045(10)70130-3 Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 Farina-Sarasqueta, 2010, The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients, Ann Oncol, 21, 2396, 10.1093/annonc/mdq258 Kalady, 2012, BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis, Dis Colon Rectum, 55, 128, 10.1097/DCR.0b013e31823c08b3 Ogino, 2012, Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, Clin Cancer Res, 18, 890, 10.1158/1078-0432.CCR-11-2246 Guastadisegni, 2010, Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data, Eur J Cancer, 46, 2788, 10.1016/j.ejca.2010.05.009 Wang, 2003, Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer, Oncology, 64, 259, 10.1159/000069311 French, 2008, Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer, Clin Cancer Res, 14, 3408, 10.1158/1078-0432.CCR-07-1489 Samowitz, 2005, Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers, Cancer Res, 65, 6063, 10.1158/0008-5472.CAN-05-0404 Ogino, 2009, CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer, Gut, 58, 90, 10.1136/gut.2008.155473 Lee, 2008, Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation, Pathol Int, 58, 104, 10.1111/j.1440-1827.2007.02197.x Hutchins, 2011, Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer, J Clin Oncol, 29, 1261, 10.1200/JCO.2010.30.1366 Nash, 2010, KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer, Ann Surg Oncol, 17, 416, 10.1245/s10434-009-0713-0 Zlobec, 2012, Stratification and prognostic relevance of Jass's molecular classification of colorectal cancer, Front Oncol, 2, 7, 10.3389/fonc.2012.00007 Newcomb, 2007, Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer, Cancer Epidemiol Biomarkers Prev, 16, 2331, 10.1158/1055-9965.EPI-07-0648 Newcomb, 2007, Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women, Cancer Res, 67, 7534, 10.1158/0008-5472.CAN-06-4275 Boland, 1998, A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res, 58, 5248 Lindor, 2002, Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors, J Clin Oncol, 20, 1043, 10.1200/JCO.2002.20.4.1043 Shia, 2008, Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry, J Mol Diagn, 10, 293, 10.2353/jmoldx.2008.080031 Buchanan, 2010, Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics, PLoS One, 5, e11636, 10.1371/journal.pone.0011636 Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Alsop, 2006, Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years, Eur J Cancer, 42, 1357, 10.1016/j.ejca.2006.02.023 The Cancer Genome Atlas. cBioPortal for Cancer Genomics. http://www.cbioportal.org/public-portal/index.do. Computational Biology Center, Memorial Sloan-Kettering Cancer Center, 2013. Imamura, 2014, Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review, Mol Cancer, 13, 135, 10.1186/1476-4598-13-135 Weisenberger, 2006, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat Genet, 38, 787, 10.1038/ng1834 Ogino, 2006, CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies, Gut, 55, 1000, 10.1136/gut.2005.082933 Hinoue, 2012, Genome-scale analysis of aberrant DNA methylation in colorectal cancer, Genome Res, 22, 271, 10.1101/gr.117523.110 van der Heijden, 2006, Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example, J Clin Epidemiol, 59, 1102, 10.1016/j.jclinepi.2006.01.015 Azur, 2011, Multiple imputation by chained equations: what is it and how does it work?, Int J Methods Psychiatr Res, 20, 40, 10.1002/mpr.329 2007 Therneau, 2000 Farcomeni, 2008, A review of modern multiple hypothesis testing, with particular attention to the false discovery proportion, Stat Methods Med Res, 17, 347, 10.1177/0962280206079046 Popat, 2005, Systematic review of microsatellite instability and colorectal cancer prognosis, J Clin Oncol, 23, 609, 10.1200/JCO.2005.01.086 Lochhead, 2013, Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication, J Natl Cancer Inst, 105, 1151, 10.1093/jnci/djt173 Ward, 2003, Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability, J Clin Oncol, 21, 3729, 10.1200/JCO.2003.03.123 Sanchez, 2009, Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer, Br J Surg, 96, 1196, 10.1002/bjs.6683 Bertagnolli, 2009, Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803, J Clin Oncol, 27, 1814, 10.1200/JCO.2008.18.2071 Sargent, 2010, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, 28, 3219, 10.1200/JCO.2009.27.1825 Jover, 2011, 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer, Gastroenterology, 140, 1174, 10.1053/j.gastro.2010.12.035 Lin, 2011, Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis, Clin Colorectal Cancer, 10, 63, 10.3816/CCC.2011.n.009 Bokemeyer, 2012, Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials, Eur J Cancer, 48, 1466, 10.1016/j.ejca.2012.02.057 Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database. Incidence - SEER 13 Regs Research Data, Nov 2011 Sub, Vintage 2009 Pops (1992–2009) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total US, 1969-2010 Counties. In: National Cancer Institute D, Surveillance Research Program, Cancer Statistics Branch, released April 2012, based on the November 2011 submission. Available at www.seer.cancer.gov. Accessed March 10, 2014.